DecisionDx-GBM – brain cancer test is a molecular diagnostic test developed at and licensed from The University of Texas M. D. Anderson Cancer Center. The test is used to prospectively predict patient outcome to treatment for glioblastoma multiforme (GBM). Four datasets were in a stepwise fashion narrowed to four common genetic signatures that are thought to be predictive of prognosis. Validation studies were then carried out in two phases. The nine genes (plus 3 control) that make up the assay are claimed to highly associated with outcome in GBM patients treated with standard therapy.
This remains an experimental approach that has not been confirmed by independent studies. There are no guidelines or consensus statements that recommend the use of this test in planning therapy or report on positive results of such a use of the test.
In general, a variety of similar tests has recently been licensed and marketed in various tumor types and at this time, none of them are generally accepted or recommended by guidelines.
Colman, et al. 2006. Meta-analysis of gene expression profiling data from glioblastoma tumor samples identifies a robust Multigene classifier predictive of survival. Proc Amer Assoc Cancer Res, Volume 47, Abstract # 5688.
Colman, et al. 2007. A robust Multigene classifier predictive of survival in patients with newly diagnosed glioblastoma. Proc Amer Assoc Cancer Res. Vol , Abstract #2700.
Aldape, et al. 2006. Meta-analysis of gene expression profiling data from glioblastoma tumor samples identifies a robust multigene classifier predictive of survival. Journal of the Society for Neuro-Oncology. Abstract GE-01.